Targeting agent for cancer cell or cancer-associated fibroblast

Abstract

Disclosed are a novel therapeutic agent and a novel treatment method for cancer. Specifically disclosed are: a targeting agent for a cell selected from the group consisting of a cancer cell and a cancer-associated fibroblast, which comprises a retinoid; a substance delivery carrier for the cell, which comprises the targeting agent; an anti-cancer composition utilizing the targeting agent or the carrier; an anti cancer-associated fibroblast composition; and a method for treatment of cancer.

1 . A targeting agent to a cell selected from the group consisting of a cancer cell and a cancer-associated fibroblast, the targeting agent comprising a retinoid. 
     
     
         2 . The targeting agent according to  claim 1 , wherein the retinoid comprises retinol. 
     
     
         3 . A substance delivery carrier to a cell selected from the group consisting of a cancer cell and a cancer-associated fibroblast, the carrier comprising the targeting agent according to  claim 1  or  2 . 
     
     
         4 . The carrier according to  claim 3 , wherein the content of the targeting agent is 0.2 to 20 wt % of the entire carrier. 
     
     
         5 . The carrier according to  claim 3  or  4 , wherein the molar ratio of the targeting agent to constituent components of the carrier other than the targeting agent is 8:1 to 1:4. 
     
     
         6 . An anticancer composition comprising the targeting agent according to  claim 1  or  2 , or the carrier according to any one of  claims 3  to  5 , and a drug that controls the activity or growth of a cancer cell and/or a cancer-associated fibroblast. 
     
     
         7 . An anti-cancer-associated fibroblast composition comprising the targeting agent according to  claim 1  or  2 , or the carrier according to any one of  claims 3  to  5 , and a drug that controls the activity or growth of a cancer-associated fibroblast. 
     
     
         8 . The composition according to  claim 6 , wherein the drug that controls the activity or growth of a cancer cell is an anticancer agent. 
     
     
         9 . The composition according to any one of  claims 6  to  8 , wherein the drug that controls the activity or growth of a cancer-associated fibroblast is selected from the group consisting of an inhibitor of activity or production of bioactive substance selected from the group consisting of TGF-β, HGF, PDGF, VEGF, IGF, MMP, FGF, uPA, cathepsin, and SDF-1, a cell activity suppressor, a growth inhibitor, an apoptosis inducer, and an siRNA, ribozyme, antisense nucleic acid, DNA/RNA chimeric polynucleotide, or vector expressing same that targets one or more molecules from among an extracellular matrix constituent molecule produced by cancer-associated fibroblasts and a molecule involved in the production or secretion of the extracellular matrix constituent molecule. 
     
     
         10 . The composition according to  claim 9 , wherein the molecule involved in the production or secretion of the extracellular matrix constituent molecule is HSP47. 
     
     
         11 . The composition according to any one of  claims 6  to  10 , wherein the drug, and the targeting agent or the carrier are mixed at a place of medical treatment or in the vicinity thereof. 
     
     
         12 . A preparation kit for the composition according to any one of  claims 6  to  11 , wherein it comprises one or more containers comprising singly or in combination the drug, the targeting agent, and as necessary carrier constituent substances other than the targeting agent.